Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C8NG
|
|||
| Former ID |
DIB007542
|
|||
| Drug Name |
BI 655064
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Lupus [ICD-11: 4A40; ICD-9: 583.81] | Phase 2 | [1] | |
| Rheumatoid arthritis [ICD-11: FA20] | Phase 1 | [2] | ||
| Thrombocytopenia [ICD-11: 3B64] | Phase 1 | [1] | ||
| Company |
Boehringer ingelheim pharmaceuticals
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02009761) Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).. U.S. National Institutes of Health. | |||
| REF 3 | FRI0167 Patient-Reported Outcomes (PROS) During Treatment with Mavrilimumab, A Fully Human Monoclonal Antibody Targeting GMCSFR-Alpha, In the Phase IIB Earth Explorer 1 Study | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.